Favrille starts NHL Phase III

As expected, Favrille began the FavId-06 Phase III trial of its FavId in 342 patients with follicular B cell non-Hodgkin's lymphoma (NHL). The trial will measure median time to disease progression. Patients will undergo biopsy and receive intravenous Rituxan for four weeks. Those whose lymphoma stabilizes or shrinks following Rituxan therapy will receive GM-CSF plus FavId or placebo. ...